Regular Research ArticlesThe Association Between Dementia and Long-Term Use of Benzodiazepine in the Elderly: Nested Case–Control Study Using Claims Data
Section snippets
Study Setting
Data for this study were obtained from the ambulatory claims database of the National Health Insurance Research Database (NHIRD). Taiwan launched a single-payer National Health Insurance (NHI) program on March 1, 1995. As of December 2003, 22.0 million individuals, representing 97% of Taiwanese population, were enrolled in this program.16 NHIs database system contains registration files, original claim data, and reimbursement data. Large computerized databases derived from this system,
RESULTS
A total of 779 cases of dementia and 4,626 of comparison subjects were included in our analysis. The mean age of this cohort was 75.6 years (SD = 9.1), with a range from 49.0 to 101.8. Cases and comparison subjects did not differ significantly in term of age (mean = 75.8 years [SD = 9.2] and 75.6 years [SD = 9.0], respectively) or sex (male ratio 46.2% and 46.4%).
Overall, 79.4% (N = 4,294) of subjects had been prescribed BZDs. Among subjects with BZDs prescribed, the mean BZDs DDD was 202.9 DDD
DISCUSSION
To the best of our knowledge, this is the first study using claims data to explore the risk of dementia and BZDs use, with population-based sampling, detailed description of BZDs prescription patterns and a well-defined method for identifying cases of dementia. We used a nested case–control design to assess BZDs exposure preceding outcome. The results, showing significant correlations between BZDs exposure and the risk of dementia, fit our hypotheses: higher cumulative dosage and longer
References (32)
- et al.
Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis
Arch Clin Neuropsychol
(2004) - et al.
Benzodiazepine use and risk of dementia: a nested case-control study
J Clin Epidemiol
(2002) - et al.
Cardiovascular disease risk factors and cognitive impairment
Am J Cardiol
(2006) - et al.
Depressive symptoms as a predictor of cognitive decline: MacArthur Studies of Successful Aging
Am J Geriatr Psychiatry
(2007) Vascular cognitive impairment
Am J Geriatr Psychiatry
(2006)- et al.
Chronic clonazepam administration induces benzodiazepine receptor subsensitivity
Neuropharmacology
(1982) - et al.
The behavioural and neuronal effects of the chronic administration of benzodiazepine anxiolytic and hypnotic drugs
Prog Neurobiol
(1996) - et al.
The accuracy of medicare claims data in identifying Alzheimer's disease
J Clin Epidemiol
(2002) - et al.
Differential association of concurrent, baseline, and average depressive symptoms with cognitive decline in older adults
Am J Geriatr Psychiatry
(2008) - et al.
Cerebrovascular disease and late-life depression
Am J Geriatr Psychiatry
(2005)
Psychotropic drug use in a representative community sample: the Upper Bavarian study
Acta Psychiatr Scand
Psychotropic drug use in elderly people with and without dementia
Int J Geriatr Psychiatry
Benzodiazepine self-administration in humans and laboratory animals—implications for problems of long-term use and abuse
Psychopharmacology (Berl)
The epidemiology of long-term benzodiazepine use
Int Rev Psychiatry
Benzodiazepines, memory and mood: a review
Psychopharmacology (Berl)
Cognitive effects of long-term benzodiazepine use: a meta-analysis
CNS Drugs
Cited by (127)
Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer's disease and insomnia: A systematic review and meta-analysis of randomized controlled trials
2021, Neuroscience and Biobehavioral ReviewsCitation Excerpt :Importantly, the management of sleep complaints with long-established hypnotics may not be advantageous and even detrimental in healthy middle-aged and elderly subjects due to the loss of cognitive function associated with these drugs (Chavant et al., 2011; Leufkens et al., 2009; Otmani et al., 2008). In addition, long-term ingestion of benzodiazepine has been linked to an increased risk of dementia (Ettcheto et al., 2020; Gray et al., 2016; He et al., 2019; Wu et al., 2009). Our systematic review showed that chronic nighttime melatonin treatment improved cognition without any detrimental effects, and daytime cognitive performance was not impaired by melatonin and consistently improve cognition with melatonin treatment when compared with placebo.
Sleep medication use and incident dementia in a nationally representative sample of older adults in the US
2021, Sleep MedicineCitation Excerpt :Also, a meta-analysis found that benzodiazepine use presents a 78% higher risk for AD compared to those not reporting use of these pharmacological medications [17]. The association between benzodiazepine use and AD in this meta-analysis focused on older adults residing outside the US (France [18–20], Taiwan [21], the United Kingdom [22], and Canada [23,24]), while only one study examined a US sample [25]. Further, the research to date has predominantly focused on benzodiazepine use and has employed study designs assessing sleep medication at baseline; participants typically did not complete regular assessment between baseline and follow-up [16].
Association between benzodiazepine use and development of dementia
2021, Medicina ClinicaUncertain Association Between Benzodiazepine Use and the Risk of Dementia: A Cohort Study
2020, Journal of the American Medical Directors AssociationCognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer's Disease: Results From NILVAD
2020, Journal of the American Medical Directors Association
The authors declare no conflict of interest.